At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.
In Brief
A Phase 2 clinical trial evaluating Nivolumab, Carboplatin, and 2 other interventions for Non-Small Cell Lung Cancer. Active but no longer recruiting, targeting 39 participants across 5 sites in 2 countries.
Detailed Summary
The proposed study will evaluate the safety and feasibility of preoperative administration nivolumab +/- ipilimumab in patients with high-risk resectable NSCLC, and will facilitate a comprehensive exploratory characterization of the tumor immune milieu and circulating immune cells and soluble factors in these patients. Data obtained in this study will provide valuable information for planning further prospective clinical trials of anti-PD-1 and other immunotherapies in NSCLC, both in the peri-operative and advanced disease setting.
Study Details
Timeline
Interventions
Anti-PD-1 Therapy
Anti-PD-1 Therapy
Anti-PD-1 Therapy
Anti-PD-1 Therapy